Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CEA antibody variable domain is fused to the C terminal of an IgG of anti-DR5 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.